Cystatins as regulators of cancer

Cox, James L.

doi:10.18103/mra.v5i7.1252

Cited by 4 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this research, cystatin C was significantly low in prostate cancer subjects compared with control. This supports the findings of Cox (2017) and Wang et al, (2018) where cystatin C was reported to be low in prostate cancer. The decreased level may be the reason for cancer progression since cystatin C is believed to play a key role in tumor suppression.…”

Section: Resultssupporting

confidence: 92%

Evaluation of Selected Renal Markers in Prostate Cancer

Oluboyo¹,

Adeleke²,

Oluboyo³

2019

Journal of Applied Sciences and Environmental Management

View full text Add to dashboard Cite

Prostate cancer is the most commonly diagnosed cancer in men and the second leading cause of cancer mortality. The study aimed to assess the level of urea, creatinine and cystatin C in prostate cancer subjects. The subjects consisted of 92 adult males between the ages of 45 to 70 years; 46 prostate cancer subjects and 46 apparently healthy subjects recruited from a Teaching Hospital in Nigeria. Urea and creatinine were estimated by colorimetric method, cystatin C was estimated using Enzyme linked immunosorbent assay (ELISA) technique. The results obtained showed that urea and creatinine were significantly high (p<0.05) while cystatin C was significantly low (p<0.05) in prostate cancer subjects compared with control subjects. Cystatin C was significantly high (p<0.05) in prostate cancer subjects on treatment compared with subjects not on treatment but there was no significant difference (p>0.05) in the levels of urea and creatinine. The research concluded that increased serum urea and creatinine concentrations as well as decreased cystatin C level may pose higher risk of renal dysfunction in prostate cancer subjects. Thus, the levels of serum urea, creatinine and cystatin C need to be evaluated in prostate cancer subjects.

show abstract

Section: Resultssupporting

confidence: 92%

Evaluation of Selected Renal Markers in Prostate Cancer

Oluboyo¹,

Adeleke²,

Oluboyo³

2019

Journal of Applied Sciences and Environmental Management

View full text Add to dashboard Cite

show abstract

“…Cysteine proteases, expressed widely in tissues, are a group of intracellular proteins with protein degradation activity which are associated with a wide variety of biological processes, including inflammation, modulation of the immune response and facilitating the progression of malignant tumors (7–9). Previous clinical studies have revealed that the cystatin superfamily proteins inhibit the proteolytic activity of cysteine proteases specifically in attenuating the aggressiveness of various malignant tumors (10–12).…”

Section: Introductionmentioning

confidence: 99%

Cystatin F as a key family 2 cystatin subunit and prognostic biomarker for early‑stage pancreatic ductal adenocarcinoma

Yang

Liu

et al. 2019

Oncol Rep

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies, and early diagnosis and assessment may enhance the quality of life and survival of patients. The prognostic value of key family 2 cystatins subunit in PDAC patients remains unknown. The potential molecular roles of family 2 cystatins and related pathways were investigated using bioinformatics analysis. The relationship of family 2 cystatin expression levels and clinical outcomes of 112 patients with early-stage PDAC were evaluated via univariate and combined survival analysis. A prognostic nomogram model was also constructed and gene set enrichment analysis was performed to investigate potential pathways in PDAC. The pathways, interaction networks, and Gene Ontology term analysis of the cystatin gene family were analyzed in the present study. Cystatin F (CST7) was identified as the key subunit of family 2 cystatins in survival analysis. PDAC patients who harbored a higher expression level of CST7 had a lower risk in overall survival (adjusted HR OS =0.44, 95% CI=0.25-0.77, P=0.004) and a longer survival time in various subgroups. The prognostic nomogram indicated that the CST7 expression model effectively predicted the outcomes of patients with early-stage PDAC (predictive ability >0.75). In the gene set enrichment analysis, it was revealed that CST7 expression may be involved in immune regulation and be associated with cell adhesion. CST7 could be a useful biomarker for the prognostic prediction of early-stage PDAC after pancreaticoduodenectomy.

show abstract